LEMAITRE VASCULAR Business Summary

LeMaitre Vascular Inc. (LMAT) operates a high-margin medical device business model focused on the design, manufacturing, and direct sale of specialized tools for peripheral vascular surgery. Revenue is primarily generated through the sale of disposable and implantable devices, alongside human tissue cryopreservation services, targeting a global network of vascular surgeons. The company’s business is segmented into core product lines including valvulotomes (the market-leading LeMaitre Valvulotome), vascular grafts (Omniflow II and ProCol), bovine pericardium patches (XenoSure), and carotid shunts. LMAT competes directly with Terumo Corporation, W. L. Gore & Associates, and Cook Medical. While these competitors often prioritize high-volume endovascular markets, LeMaitre maintains a dominant competitive advantage by specializing in the 'open' vascular surgery niche, where it commands significant pricing power and brand loyalty. Founded in 1983 by vascular surgeon Dr. George D. LeMaitre, the company is currently led by his son, Chairman and CEO George W. LeMaitre, a Stanford GSB alumnus who has overseen the firm’s expansion into a global enterprise. The executive team includes President David B. Roberts, who manages international operations and strategic growth, and CFO Joseph P. Pellegrino, who provides veteran financial leadership in the med-tech sector. The company's governance is bolstered by a board featuring seasoned industry figures like Martha Shadan and John J. O'Connor. LeMaitre maintains a strong institutional investor base, with significant positions held by BlackRock, Vanguard, and T. Rowe Price, reflecting the company’s track record of disciplined capital allocation and consistent dividend growth.